Keyphrases
Acute Lymphoblastic Leukemia
67%
Pediatric Patients
60%
Pediatric
59%
Pediatric Leukemia
55%
Acute Myeloid Leukemia
45%
Netherlands
42%
Pharmacokinetics
34%
Leukemia
29%
KMT2A
27%
Dutch
24%
Population Pharmacokinetics
21%
Phase II Study
21%
Newly Diagnosed
21%
Pediatric Oncology
20%
Improved Survival
20%
Gemtuzumab Ozogamicin
19%
Leukemia Patients
19%
Older Adults
18%
Relapsed or Refractory
18%
Young Adolescents
18%
Confidence Interval
17%
Children with Cancer
17%
Hematopoietic Stem Cells
16%
Neuroblastoma
16%
Bone Marrow
15%
Preadolescent children
15%
Overall Survival
15%
High-risk Neuroblastoma
14%
Pediatric Acute Lymphoblastic Leukemia
14%
Hematopoietic Stem Cell Transplantation
13%
Down Syndrome
13%
Average Annual Percentage Change
12%
Acute Leukemia
12%
T Cells
12%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
12%
Oncology
12%
CD22
12%
Pediatric Cancer
11%
Chronic Myeloid Leukemia
11%
Population-based Study
11%
Myelodysplastic Syndrome
11%
5-year Survival
11%
Clinical Outcomes
11%
Minimal Residual Disease
10%
Relapsed or Refractory Acute Myeloid Leukemia
10%
Precision Oncology
10%
Cancer-related Fatigue
10%
Aprepitant
10%
Neonate
10%
Azacitidine
10%
Genome Analysis
10%
DOT1L Inhibitor
10%
Chemotherapy
10%
Clinical Trials
10%
Childhood Acute Lymphoblastic Leukemia
10%
Treatment Response
9%
BCP-ALL
9%
Event-free Survival
9%
Menin Inhibitors
9%
Nup98
9%
Cancer Registry
9%
Immune Dysregulation
9%
Improved Outcomes
9%
Hodgkin Lymphoma
8%
Clinically Significant
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
8%
Pediatric AML
8%
Dose-limiting Toxicity
8%
Vulnerability
8%
Chimeric Antigen Receptor T-cell Therapy
8%
Wilms Tumor
8%
Normal Blood
8%
Sleep Problems
8%
Young Cancer Patients
8%
Paediatric Strategy Forum
8%
Non-Hodgkin Lymphoma
8%
Solid Tumors
8%
Working Diagnosis
8%
Targeted Therapy
8%
Recommended Phase 2 Dose
7%
Incidence Trends
7%
European Medicines Agency
7%
Group Studies
7%
Fusion Gene
7%
Acquired Resistance
7%
Preleukemic
7%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
7%
High Risk
7%
Patient Outcomes
7%
Complete Remission
7%
Risk Factors
7%
Innovative Therapies
7%
Drug Development
7%
Survival Rate
7%
Clofarabine
7%
Sleep-wake Rhythm
7%
Nilotinib
7%
Treatment Effect
7%
Medullary Thyroid Cancer
7%
Targeted Treatment
7%
Medicine and Dentistry
Pediatrics
100%
Acute Lymphoblastic Leukemia
62%
Acute Myeloid Leukemia
56%
Pediatric Acute Myeloid Leukemia
54%
Adolescence
47%
Ganglioneuroblastoma
38%
Pediatrics Patient
37%
Malignant Neoplasm
33%
Neoplasm
28%
Overall Survival
27%
Disease
25%
Childhood Cancer
25%
Oncology
23%
Leukemia
22%
Acute Myelogenous Leukemia
20%
Immunotherapy
19%
Targeted Therapy
16%
Diseases
16%
Inotuzumab Ozogamicin
15%
Acute Leukemia
13%
Cancer
13%
Minimal Residual Disease
13%
Down Syndrome
12%
Pediatric Cancer
12%
Clinical Trial
12%
Leukemia in Children
12%
Personalized Medicine
11%
Dexamethasone
10%
Hematopoietic Stem Cell Transplantation
10%
Event Free Survival
10%
Hematopoietic Cell
10%
Maintenance Therapy
10%
Hodgkin's Lymphoma
9%
Somatics
9%
Chemotherapy
9%
Cancer Registry
9%
Treatment Response
8%
Solid Malignant Neoplasm
8%
Phase II Trials
8%
Survival Rate
8%
Fusion Gene
8%
Progression Free Survival
8%
Side Effect
8%
Kidney Tumour
8%
T Cell
8%
Medicine
7%
Transcriptomics
7%
Adverse Outcome
7%
Methionine
7%
Randomized Controlled Trial
7%
Wilms' Tumor
7%
Cancer-Related Fatigue
7%
Sleep Waking Cycle
7%
Retrospective Study
7%
Topotecan
7%
Immune Dysregulation
7%
Juvenile Myelomonocytic Leukemia
7%
Chromosome 13
7%
Liquid Biopsy
7%
Azacitidine
7%
Temozolomide
7%
Myelodysplastic Syndrome
7%
Disease Modifying Therapy
7%
B Cell
6%
Diagnosis
6%
High Throughput Screening
6%
In Vitro
6%
Leukemia Cell
6%
Central Nervous System Tumor
6%
Anaplastic Lymphoma Kinase
5%
Arm
5%
Experimental Therapy
5%
High Risk Population
5%
Non-Hodgkin Lymphoma
5%
Lymphoblastic Lymphoma
5%
Chimeric Antigen Receptor T-Cell
5%
Catecholamine
5%
Trisomy
5%
Mortality Rate
5%
Precursor
5%
NPM1
5%